Investment Analysts’ Recent Ratings Changes for Crinetics Pharmaceuticals (CRNX)

Several analysts have recently updated their ratings and price targets for Crinetics Pharmaceuticals (NASDAQ: CRNX):

• 1/12/2026 – Crinetics Pharmaceuticals was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $67.00 price target on the stock.
• 1/8/2026 – Crinetics Pharmaceuticals had its price target lowered by analysts at Citizens Jmp from $108.00 to $105.00. They now have a “market outperform” rating on the stock.
• 1/6/2026 – Crinetics Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $77.00 to $80.00. They now have an “overweight” rating on the stock.
• 1/3/2026 – Crinetics Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Activity

In related news, insider Dana Pizzuti sold 5,000 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $42.66, for a total transaction of $213,300.00. Following the transaction, the insider directly owned 66,270 shares of the company’s stock, valued at $2,827,078.20. This trade represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Isabel Kalofonos sold 2,500 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $55.00, for a total transaction of $137,500.00. Following the completion of the transaction, the insider directly owned 834 shares in the company, valued at approximately $45,870. The trade was a 74.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 6.00% of the company’s stock.

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.